Search

everythinglearnresearchcommunity

for

Search:↓

TB lymphadenitis can occur in people with weakened immune systems, like those with SLE.

Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Anti-cancer drugs are diverse and hard to classify due to their different forms and actions.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Five FDA-approved drugs may help block COVID-19 virus entry.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

Early recognition and management of gastrointestinal tuberculosis in lupus patients are crucial to prevent complications.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Itraconazole helps improve tough skin infections but may not prevent them from coming back.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

Buffaloes with skin issues were cured using tetracycline injections.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

These new skin treatments are safer and more effective with minimal side effects.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Multitarget drugs are needed to better treat complex diseases.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.

Deltsid 7.5 is the most effective treatment for bovine psoroptosis.

Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.